Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT06144840




Registration number
NCT06144840
Ethics application status
Date submitted
17/11/2023
Date registered
22/11/2023
Date last updated
13/05/2024

Titles & IDs
Public title
INcreased Sun Exposure Without Pain In Research Participants With EPP or XLP
Scientific title
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy, Safety, and Tolerability of MT-7117 in Adults and Adolescents With Erythropoietic Protoporphyria or X-Linked Protoporphyria
Secondary ID [1] 0 0
jRCT2031230656
Secondary ID [2] 0 0
MT-7117-A-302
Universal Trial Number (UTN)
Trial acronym
INSPIRE
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Erythropoietic Protoporphyria (EPP) 0 0
X-Linked Protoporphyria (XLP) 0 0
Condition category
Condition code
Skin 0 0 0 0
Other skin conditions
Blood 0 0 0 0
Other blood disorders
Human Genetics and Inherited Disorders 0 0 0 0
Other human genetics and inherited disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Dersimelagon
Treatment: Drugs - Placebo

Experimental: MT-7117 -

Placebo Comparator: Placebo -


Treatment: Drugs: Dersimelagon
MT-7117

Treatment: Drugs: Placebo
Placebo
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Change from baseline in average daily sunlight exposure time (minutes) to first prodromal symptom (burning, tingling, itching, or stinging) associated with sunlight exposure between 1 hour post-sunrise and 1 hour pre-sunset at Week 16
Timepoint [1] 0 0
Week 16
Secondary outcome [1] 0 0
Patient Global Impression of Change (PGIC) at Week 16.
Timepoint [1] 0 0
Week 16
Secondary outcome [2] 0 0
Total number of sunlight-induced pain events defined as prodromal symptoms (burning, tingling, itching, or stinging) with pain rating of 1-10 on the Likert scale during the 16-week double-blind treatment period.
Timepoint [2] 0 0
Week 16
Secondary outcome [3] 0 0
Total number of sunlight-induced non-prodrome, phototoxic reactions during the 16-week double-blind treatment period.
Timepoint [3] 0 0
Week 16

Eligibility
Key inclusion criteria
1. Subjects provided written informed consent to participate. For minor subjects, both
minor's assent and parental consent will be required.

2. Male and female subjects with a confirmed diagnosis of EPP or XLP based on medical
history.

3. Subjects aged 12 years to 75 years, inclusive, at Screening.

4. Subjects are willing and able to travel to the study sites for all scheduled visits.

5. In the Investigator's opinion, subject can understand the nature of the study and any
risks involved in participation, and willing to cooperate and comply with the protocol
restrictions and requirements (including travel and receiving direct sunlight exposure
as much as possible).

6. Female subjects who are non-lactating and have a negative urine pregnancy test at
baseline visit prior to receiving the first dose of study drug.

7. Female subjects of childbearing potential and male subjects with partner of
child-bearing potential currently using/willing to use 2 effective methods of
contraception.

Additional screening criteria check may apply for qualification.
Minimum age
12 Years
Maximum age
75 Years
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
1. History or presence of photodermatoses other than EPP or XLP.

2. Subjects who are unwilling or unable to go outside in sunlight during daylight hours
most days (e.g., between 1-hour post-sunrise and 1 hour pre-sunset) during the study.

3. Presence or history of any hepatobiliary disease, including druginduced liver injury
at screening, determined as clinically significant by the Investigator after the
discussion with the Sponsor Medical Monitor.

4. Subjects with aspartate aminotransferase (AST), alanine aminotransferase (ALT),
alkaline phosphatase (ALP) = 2.0 × upper limit of normal (ULN) or total bilirubin >1.5
× ULN at Screening.

5. History (in the last 2 years) or presence of alcohol abuse, or abuse of illicit drugs
in the opinion of the Investigator.

6. History of melanoma.

7. Presence of squamous cell carcinoma, basal cell carcinoma, or other malignant skin
lesions. Any suspicious lesions or nevi will be evaluated. If the suspicious lesion or
nevi cannot be resolved through biopsy or excision, the subject will be excluded from
the study.

8. History or presence of psychiatric disease judged to be clinically significant by the
Investigator and which may interfere with the study evaluation and/or safety of the
subjects.

9. Presence of clinically significant acute or chronic renal disease or subjects with an
estimated glomerular filtration rate (eGFR) <60 mL/min as calculated by the Chronic
Kidney DiseaseEpidemiology Collaboration (CKD-EPI) creatinine equation (2021) for
adults and by the Schwartz creatinine equation for adolescents (2009). Modification of
Diet in Renal Disease can be used for adults per local recommendations.

10. Presence of any clinically significant disease or laboratory abnormality which, in the
opinion of the Investigator, can interfere with the study objectives and/or safety of
the subjects.

11. Female subjects who are pregnant, lactating, or intending to become pregnant during
the study.

12. Treatment with any of the following medications or therapy within each period before
Randomization (Visit 2);

- Afamelanotide within 3 months

- Phototherapy within 3 months

- Cimetidine within 4 weeks

- Antioxidant agents within 4 weeks, at doses which, in the opinion of the
Investigator, may affect study endpoints (including but not limited to
beta-carotene, cysteine, pyridoxine).

- Chronic treatment with any scheduled analgesic agents including, but not limited
to, opioids and opioid derivatives such as morphine, hydrocodone, oxycodone,
fentanyl, or their combination with other unscheduled analgesics or non-steroidal
anti-inflammatory drug (Percocet and Vicodin-like prescription drugs) within 4
weeks.

Note: Acute use of scheduled narcotics more than 3 months prior to randomization are
allowed. Non-steroidal anti-inflammatory drug, aspirin for analgesia, or prior
temporary use of scheduled agents within 3 months of screening is allowed.

13. Dermatological treatments with any drugs or supplements which, in the opinion of the
Investigator, can interfere with the objectives of the study or safety of the subjects
at screening, such as, for example, tanning agents.

14. Subjects who participated in any previous MT-7117 clinical studies.

15. Previous treatment with any investigational agent such as bitopertin, within 12 weeks
before Screening or 5 half-lives of the investigational product (whichever is longer).

16. Use of sunscreens with zinc oxide. Note: Sunscreens without zinc oxide are allowed,
however their use, in frequency, quantity and body surface area should be maintained
relatively stable throughout the duration of the study.

17. History of any hypersensitivity to the active ingredient and/or excipients (lactose
monohydrate, hydroxypropylcellulose, carmellose calcium, magnesium stearate,
hypromellose, titanium dioxide, talc, polyethylene glycol, iron oxide yellow, iron
oxide red, and iron oxide black). (EU ONLY)

18. Subjects who are unable to swallow tablets or have diseases significantly affecting
the gastrointestinal function such as malabsorption syndrome, resection of the stomach
or small bowel, bariatric surgery procedures, symptomatic inflammatory bowel disease,
or partial or complete bowel obstruction.(EU ONLY)

19. History of any hypersensitivity to the active ingredient and/or excipients contained
in MT-7117 IMP (lactose monohydrate, hydroxypropyl cellulose, carmellose calcium,
magnesium stearate, hypromellose, titanium dioxide, talc, polyethylene glycol, iron
oxide yellow, iron oxide red, and iron oxide black). (UK ONLY)

Additional screening criteria check may apply for qualification.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s
The people administering the treatment/s
The people assessing the outcomes
The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
11/12/2023
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
1/06/2026
Actual
Sample size
Target
150
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,VIC
Recruitment hospital [1] 0 0
Royal Prince Alfred Hospital - Camperdown
Recruitment hospital [2] 0 0
Royal Melbourne Hospital (RMH) - Parkville
Recruitment postcode(s) [1] 0 0
02050 - Camperdown
Recruitment postcode(s) [2] 0 0
03050 - Parkville
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
California
Country [2] 0 0
United States of America
State/province [2] 0 0
Florida
Country [3] 0 0
United States of America
State/province [3] 0 0
Massachusetts
Country [4] 0 0
United States of America
State/province [4] 0 0
Michigan
Country [5] 0 0
United States of America
State/province [5] 0 0
Missouri
Country [6] 0 0
United States of America
State/province [6] 0 0
New York
Country [7] 0 0
United States of America
State/province [7] 0 0
North Carolina
Country [8] 0 0
United States of America
State/province [8] 0 0
Ohio
Country [9] 0 0
United States of America
State/province [9] 0 0
Pennsylvania
Country [10] 0 0
United States of America
State/province [10] 0 0
Texas
Country [11] 0 0
United States of America
State/province [11] 0 0
Washington
Country [12] 0 0
Bulgaria
State/province [12] 0 0
Sofia
Country [13] 0 0
Czechia
State/province [13] 0 0
Prague
Country [14] 0 0
France
State/province [14] 0 0
Bordeaux
Country [15] 0 0
France
State/province [15] 0 0
Nantes
Country [16] 0 0
France
State/province [16] 0 0
Paris
Country [17] 0 0
Italy
State/province [17] 0 0
Brescia
Country [18] 0 0
Italy
State/province [18] 0 0
Cuneo
Country [19] 0 0
Italy
State/province [19] 0 0
Genova
Country [20] 0 0
Italy
State/province [20] 0 0
Milan
Country [21] 0 0
Italy
State/province [21] 0 0
Modena
Country [22] 0 0
Italy
State/province [22] 0 0
Rome
Country [23] 0 0
Italy
State/province [23] 0 0
Trieste
Country [24] 0 0
Japan
State/province [24] 0 0
Hiroshima-ken
Country [25] 0 0
Japan
State/province [25] 0 0
Shizuoka
Country [26] 0 0
Japan
State/province [26] 0 0
Tokyo
Country [27] 0 0
Netherlands
State/province [27] 0 0
Rotterdam
Country [28] 0 0
Poland
State/province [28] 0 0
Warsaw
Country [29] 0 0
Spain
State/province [29] 0 0
Madrid
Country [30] 0 0
Spain
State/province [30] 0 0
Valencia
Country [31] 0 0
United Kingdom
State/province [31] 0 0
London
Country [32] 0 0
United Kingdom
State/province [32] 0 0
Southamption

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Mitsubishi Tanabe Pharma America Inc.
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
To investigate the efficacy of MT-7117 on time to onset and severity of first prodromal
symptoms (burning, tingling, itching, or stinging) associated with sunlight exposure in
adults and adolescents with EPP or XLP.
Trial website
https://clinicaltrials.gov/ct2/show/NCT06144840
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Head of Medical Science
Address 0 0
Mitsubishi Tanabe Pharma America Inc.
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Clinical Trials Information Desk, To prevent mis-communication,
Address 0 0
Country 0 0
Phone 0 0
please email:
Fax 0 0
Email 0 0
information@mt-pharma-us.com
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/ct2/show/NCT06144840